Cargando…

EZH2 inactivation in RAS-driven myeloid neoplasms hyperactivates RAS-signaling and increases MEK inhibitor sensitivity

Detalles Bibliográficos
Autores principales:	Berg, Johannes Lorenz, Perfler, Bianca, Hatzl, Stefan, Uhl, Barbara, Reinisch, Andreas, Pregartner, Gudrun, Berghold, Andrea, Penz, Thomas, Schuster, Michael, Geissler, Klaus, Prokesch, Andreas, Müller-Tidow, Carsten, Hoefler, Gerald, Kashofer, Karl, Wölfler, Albert, Sill, Heinz, Caraffini, Veronica, Zebisch, Armin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2021
Materias:	Letter
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8102185/ https://www.ncbi.nlm.nih.gov/pubmed/33589750 http://dx.doi.org/10.1038/s41375-021-01161-0

Ejemplares similares

Loss of RAF kinase inhibitor protein is involved in myelomonocytic differentiation and aggravates RAS-driven myeloid leukemogenesis
por: Caraffini, Veronica, et al.
Publicado: (2020)

Micro-RNA-125a mediates the effects of hypomethylating agents in chronic myelomonocytic leukemia
por: Berg, Johannes Lorenz, et al.
Publicado: (2021)

Increased Expression of Micro-RNA-23a Mediates Chemoresistance to Cytarabine in Acute Myeloid Leukemia
por: Hatzl, Stefan, et al.
Publicado: (2020)

Detection of prognostically relevant mutations and translocations in myeloid sarcoma by next generation sequencing
por: Kashofer, Karl, et al.
Publicado: (2017)

Onco-immunomodulatory properties of pharmacological interference with RAS-RAF-MEK-ERK pathway hyperactivation
por: Avery, Thomas Yul, et al.
Publicado: (2022)

Ras hyperactivation versus overexpression: Lessons from Ras dynamics in Candida albicans
por: Pratyusha, Vavilala A., et al.
Publicado: (2018)

Comparison of acute myeloid leukemia and myelodysplastic syndromes with TP53 aberrations
por: Dutta, Sayantanee, et al.
Publicado: (2022)

Therapeutic Resistance in Acute Myeloid Leukemia: The Role of Non-Coding RNAs
por: Zebisch, Armin, et al.
Publicado: (2016)

Author Correction: Ras hyperactivation versus overexpression: Lessons from Ras dynamics in Candida albicans
por: Pratyusha, Vavilala A., et al.
Publicado: (2019)

Clinical implications of subclonal TP53 mutations in acute myeloid leukemia
por: Prochazka, Katharina T., et al.
Publicado: (2019)

RAF Kinase Inhibitor Protein in Myeloid Leukemogenesis
por: Zebisch, Armin, et al.
Publicado: (2019)

MEK targeting in N-RAS mutated metastatic melanoma
por: Thumar, Jaykumar, et al.
Publicado: (2014)

Sensitive and broadly applicable residual disease detection in acute myeloid leukemia using flow cytometry‐based leukemic cell enrichment followed by mutational profiling
por: Daga, Shruti, et al.
Publicado: (2020)

High GPR56 surface expression correlates with a leukemic stem cell gene signature in CD34‐positive AML
por: Daga, Shruti, et al.
Publicado: (2019)

Response and Resistance to MEK Inhibition in Leukaemias Initiated by Hyperactive Ras
por: Lauchle, Jennifer O., et al.
Publicado: (2009)

BRAF(V600E) promotes DC3/monocyte differentiation in human gene-engineered HSPCs and causes multisystem histiocytosis
por: Sconocchia, Tommaso, et al.
Publicado: (2023)

Nf1 Loss and Ras Hyperactivation in Oligodendrocytes Induce NOS-Driven Defects in Myelin and Vasculature
por: Mayes, Debra A., et al.
Publicado: (2013)

Hyperactivation of ERK by multiple mechanisms is toxic to RTK-RAS mutation-driven lung adenocarcinoma cells
por: Unni, Arun M, et al.
Publicado: (2018)

Human gene-engineered calreticulin mutant stem cells recapitulate MPN hallmarks and identify targetable vulnerabilities
por: Foßelteder, Johannes, et al.
Publicado: (2023)

Detection of AML-specific TP53 mutations in bone marrow–derived mesenchymal stromal cells cultured under hypoxia conditions
por: Müller, Marian, et al.
Publicado: (2019)

Reversal of the Ras-Induced Transformed Phenotype by Hr12, a Novel Ras Farnesylation Inhibitor, Is Mediated by the Mek/ERK Pathway
por: Reuveni, Hadas, et al.
Publicado: (2000)

Polymorphisms in RAS/RAF/MEK/ERK Pathway Are Associated with Gastric Cancer
por: Gonzalez-Hormazabal, Patricio, et al.
Publicado: (2018)

Targeting Aberrant RAS/RAF/MEK/ERK Signaling for Cancer Therapy
por: Degirmenci, Ufuk, et al.
Publicado: (2020)

Oncogenic Ras mutant causes the hyperactivation of NF‐κB via acceleration of its transcriptional activation
por: Tago, Kenji, et al.
Publicado: (2019)

Hyperactivated RAGE in Comorbidities as a Risk Factor for Severe COVID-19—The Role of RAGE-RAS Crosstalk
por: Chiappalupi, Sara, et al.
Publicado: (2021)

Targeted elimination of senescent Ras-transformed cells by suppression of MEK/ERK pathway
por: Kochetkova, Elena Y., et al.
Publicado: (2017)

Efficacy of MEK inhibition in a K-Ras-driven cholangiocarcinoma preclinical model
por: Dong, Mingjie, et al.
Publicado: (2018)

Correlation between MEK signature and Ras gene alteration in advanced gastric cancer
por: Ahn, Soomin, et al.
Publicado: (2017)

Combined targeting of MEK and the glucocorticoid receptor for the treatment of RAS-mutant multiple myeloma
por: Sriskandarajah, Priya, et al.
Publicado: (2020)

Sensitivity and Resistance of Oncogenic RAS-Driven Tumors to Dual MEK and ERK Inhibition
por: Catalano, Antonella, et al.
Publicado: (2021)

Reusability and composability in process description maps: RAS–RAF–MEK–ERK signalling
por: Mazein, Alexander, et al.
Publicado: (2021)

Functional Classification of TP53 Mutations in Acute Myeloid Leukemia
por: Dutta, Sayantanee, et al.
Publicado: (2020)

CREBBP knockdown enhances RAS/RAF/MEK/ERK signaling in Ras pathway mutated acute lymphoblastic leukemia but does not modulate chemotherapeutic response
por: Dixon, Zach A., et al.
Publicado: (2017)

Dynamic regulation of RAS and RAS signaling
por: Kolch, Walter, et al.
Publicado: (2023)

Modulation of the Akt/Ras/Raf/MEK/ERK pathway by A(3) adenosine receptor
por: Merighi, Stefania, et al.
Publicado: (2006)

The Ras/Raf/MEK/ERK signaling pathway and its role in the occurrence and development of HCC
por: Li, Lei, et al.
Publicado: (2016)

Enhancement of Cancer-Specific Protoporphyrin IX Fluorescence by Targeting Oncogenic Ras/MEK Pathway
por: Yoshioka, Ema, et al.
Publicado: (2018)

RDM1 promotes neuroblastoma growth through the RAS–Raf–MEK–ERK pathway
por: Xie, Guojin, et al.
Publicado: (2019)

Targeting RAS Mutant Colorectal Cancer with Dual Inhibition of MEK and CDK4/6
por: Sorokin, Alexey V., et al.
Publicado: (2022)

RAS-dependent RAF-MAPK hyperactivation by pathogenic RIT1 is a therapeutic target in Noonan syndrome–associated cardiac hypertrophy
por: Cuevas-Navarro, Antonio, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_tedd6n5o01sck42nq7s58e6me5